| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
|
| Targets |
Chloride Channel[1]
|
|---|---|
| ln Vitro |
In endothelial cells, fenamic acid (N-Phenylanthranilic acid, NPAA) (2.5 mM; 3 h) inhibits Cl-transport and prevents 36C1-uptake and efflux[1][2]. Fenamic acid suppresses AKR1B10 with IC50s of 0.76 μM for flufenamic acid, 1.6 μM for mefenamic acid, and 9.89 μM for meclofenamic acid, respectively. Fenamic acid shows selectivity to AKR1B10 (the tumor-marker) over human AR[4]. 50% of Neisseria gonorrhoeae with a MIC50 value between 4 and 16 µg/mL (tolfenamic acid, flufenamic acid, and meclofenamic acid) in a low frequency of resistance are inhibited by fenamic acid (4–16 μg/mL; 72 h)[5]. When applied to infected endocervical cells, fenamic acid (2–8 µg/mL; 8 h) decreases the expression of porinflammatory cytokines (IL–8, IL–6, and IL-ß) without inhibiting the cells' ability to bind commensally to Lactobacillus species (>128 µg/mL; 24 h). being a member of a healthy female vaginal microbiota[5].
|
| ln Vivo |
RPA-1 is a biomarker used to identify collecting duct damage in male rats with papillary necrosis[3]. In rats, fenamic acid (N-Phenylanthranilic acid, NPAA) (350–700 mg/kg/day; op; 4 d, 8 d, and 15 d) increases urine renal papillary antigen-1 (RPA-1) and promotes renal papillary necrosis[3]. Mice's abdominal constriction caused by acetic acid is inhibited by fenamic acid (20 g/0.2 mL; ip)[6].
|
| Animal Protocol |
Animal/Disease Models: Male Wistar Hannover rats (8-10 weeks old; weighting 220-270 g)[3]
Doses: 50, 350, or up to 700 mg/kg Route of Administration: Oral gavage; one time/day; 7 days or 14 days Experimental Results: Increased absolute paired kidney weights (13.8% at 350 mg/kg and 21.2% at 700/500 mg/kg) and relative to body weight (10.5% at 350 mg/kg/day and 20.3% at 700/500 mg/kg/day). Caused minimal papillary necrosis of tip with necrosis, hemorrhage, and inflammation of collecting ducts. Animal/Disease Models: Male NMRI mice (weighting 20-25 g); abdominal constriction model (writhing test), induced by acetic acid[6] Doses: 100 g/mL, each mice injected with 20 mL Route of Administration: intraperitoneal (ip) injection; once Experimental Results: demonstrated anti-nociceptive activity and inhibited the abdominal constriction with the maximal inhibition of 96.3% (Mefenamic acid). |
| References |
|
| Additional Infomation |
Fenamic acid is an aminobenzoic acid that is the N-phenyl derivative of anthranilic acid. It acts as a parent skeleton for the synthesis of several non-steroidal anti-inflammatory drugs. It has a role as a membrane transport modulator. It is a secondary amino compound and an aminobenzoic acid. It is functionally related to an anthranilic acid.
|
| Molecular Formula |
C13H11NO2
|
|---|---|
| Molecular Weight |
213.23
|
| Exact Mass |
213.078
|
| CAS # |
91-40-7
|
| PubChem CID |
4386
|
| Appearance |
Yellow to khaki solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
385.2±25.0 °C at 760 mmHg
|
| Melting Point |
182-185 °C(lit.)
|
| Flash Point |
186.7±23.2 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.667
|
| LogP |
4.41
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
16
|
| Complexity |
236
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZWJINEZUASEZBH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H11NO2/c15-13(16)11-8-4-5-9-12(11)14-10-6-2-1-3-7-10/h1-9,14H,(H,15,16)
|
| Chemical Name |
2-anilinobenzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (586.22 mM)
H2O: < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.17 mg/mL (19.56 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 41.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6898 mL | 23.4489 mL | 46.8977 mL | |
| 5 mM | 0.9380 mL | 4.6898 mL | 9.3795 mL | |
| 10 mM | 0.4690 mL | 2.3449 mL | 4.6898 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
